Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial

AIM: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in predefined (</≥65 years) and post hoc (</≥70 years) age groups of people with type 2 diabetes (T2D) in the BRIGHT trial. MATERIALS AND METHODS: BRIGHT was the first he...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Autores principales: Bolli, Geremia B., Cheng, Alice, Charbonnel, Bernard, Aroda, Vanita R., Westerbacka, Jukka, Bosnyak, Zsolt, Boëlle‐Le Corfec, Emmanuelle, Rosenstock, Julio
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252805/
https://ncbi.nlm.nih.gov/pubmed/33687748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14372
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares